npj Vaccines

npj Vaccines, Published online: 19 June 2026; doi:10.1038/s41541-026-01505-w Oral Rotavirus vaccines have reduced disease globally but multiple factors in low- and middle-income countries (LMICs) diminish vaccine effectiveness and disease burden remains high. A convening of experts reviewed advances in mucosal immunity, disease model systems, lessons from other pathogens and the lack of correlate…

npj Vaccines, Published online: 19 June 2026; doi:10.1038/s41541-026-01503-y Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma

npj Vaccines, Published online: 10 June 2026; doi:10.1038/s41541-026-01500-1 Evaluating large language models on multilingual vaccine knowledge: a benchmark study

npj Vaccines, Published online: 08 June 2026; doi:10.1038/s41541-026-01491-z Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB

npj Vaccines, Published online: 05 June 2026; doi:10.1038/s41541-026-01499-5 Response to vaccination and immune status after intrauterine exposure to immunomodulating drugs for maternal IBD

npj Vaccines, Published online: 04 June 2026; doi:10.1038/s41541-026-01495-9 Population-level impact of quadrivalent HPV vaccination in Brazil: a repeated cross-sectional study

npj Vaccines, Published online: 05 June 2026; doi:10.1038/s41541-026-01498-6 Genetically diverse CC and DO mouse models enable comprehensive assessments of novel tuberculosis vaccines

npj Vaccines, Published online: 03 June 2026; doi:10.1038/s41541-026-01496-8 Chitosan nanoparticles for mucosal and needle-free vaccination

npj Vaccines, Published online: 02 June 2026; doi:10.1038/s41541-026-01501-0 Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populations

npj Vaccines, Published online: 29 May 2026; doi:10.1038/s41541-026-01470-4 Author Correction: Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation

npj Vaccines, Published online: 28 May 2026; doi:10.1038/s41541-026-01490-0 MVA-BN monkeypox vaccine safety in a clinical trial in the Democratic Republic of the Congo

npj Vaccines, Published online: 26 May 2026; doi:10.1038/s41541-026-01493-x Trends in funding for coronavirus vaccine research and development: implications for preparedness against future coronavirus threats

npj Vaccines, Published online: 26 May 2026; doi:10.1038/s41541-026-01492-y Seasonal influenza mRNA vaccine induces stronger innate and comparable or better adaptive responses than licensed inactivated vaccines

npj Vaccines, Published online: 23 May 2026; doi:10.1038/s41541-026-01494-w Heterologous vaccination with a next-generation vaccinia virus and Ad26 induces Ebola-specific immunity in macaques

npj Vaccines, Published online: 22 May 2026; doi:10.1038/s41541-026-01483-z Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy

npj Vaccines, Published online: 21 May 2026; doi:10.1038/s41541-026-01488-8 The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines

npj Vaccines, Published online: 20 May 2026; doi:10.1038/s41541-026-01486-w Recent advances in Epstein–Barr virus vaccines development from mechanistic exploration to clinical translation

npj Vaccines, Published online: 19 May 2026; doi:10.1038/s41541-026-01489-7 Vaccination in individuals with Down syndrome: immune vulnerability, safety, efficacy and opportunities

npj Vaccines, Published online: 18 May 2026; doi:10.1038/s41541-026-01487-9 Vaccine communication: a critical review of foundations, challenges, and future directions

npj Vaccines, Published online: 16 May 2026; doi:10.1038/s41541-026-01485-x β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris